MWVC
OPTR

Morgens Waterfall Vintiadis & Co’s OPTIMER PHARMACEUTICALS, INC. COM STK OPTR Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio OPTR Stock Details OPTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-255,000
Closed -$3.69M – 59
2013
Q2 		$3.69M Buy
+255,000
New +$3.71M 2.81% 14

Other funds holding OPTR

WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Alpine Associates Advisors Englewood Cliffs, New Jersey $158M AUM 48.85% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's OPTR Position: Q3 2013 in Review

Morgens Waterfall Vintiadis & Co sold out of OPTIMER PHARMACEUTICALS, INC. COM STK (OPTR) in Q3 2013, closing a stake of 255,000 shares — an estimated $3.69M sold.

Morgens Waterfall Vintiadis & Co first reported a position in OPTR in Q2 2013 and held it in 1 quarter. The position peaked at $3.69M in Q2 2013. 104 funds tracked by Wall St. Rank hold OPTR as of Q3 2013.

  • Morgens Waterfall Vintiadis & Co reported no remaining OPTIMER PHARMACEUTICALS, INC. COM STK position as of Q3 2013 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 255,000 OPTIMER PHARMACEUTICALS, INC. COM STK shares in Q3 2013, an estimated $3.69M.
  • Morgens Waterfall Vintiadis & Co first reported a position in OPTIMER PHARMACEUTICALS, INC. COM STK in Q2 2013 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's OPTIMER PHARMACEUTICALS, INC. COM STK position peaked at $3.69M in Q2 2013.
  • 104 funds tracked by Wall St. Rank held OPTIMER PHARMACEUTICALS, INC. COM STK as of Q3 2013.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q3 2013, filed 29 Oct 2013.